NeuroOne Medical Technologies (NASDAQ: NMTC) saw a small insider sale this month when Business Development Director Mark Christianson disposed of 917 shares of common stock over two trading sessions. The transactions took place on March 12 and March 13, 2026, and netted approximately $733 in total proceeds.
The trades were executed in two tranches: 817 shares were sold on March 12 at $0.8 per share, followed by a further 100 shares sold on March 13 at the same $0.8 price. Following these sales, Christianson retained a direct ownership stake of 214,283 shares in the company.
Market pricing since those trades shows the stock at $0.72, reflecting a 30% decline over the past year. The sale size and value were modest relative to Christianson’s remaining holding, and in isolation represent a limited change to his overall ownership position.
Separately, NeuroOne released its Q1 fiscal 2026 results, reporting a net loss of $1.4 million, or $0.03 per share. That result was smaller than analyst expectations of a $0.04 per-share loss. Revenue for the quarter totaled $2.9 million, marginally above the $2.86 million that had been forecast.
Analysts and platform analyses referenced alongside the company’s reporting paint a mixed picture. InvestingPro’s analysis lists NeuroOne on its Most Undervalued list based on Fair Value calculations, indicating that some valuation metrics may suggest upside relative to current market pricing. Meanwhile, Jones Trading has initiated coverage on the company with a Buy rating and a $1.50 price target.
Jones Trading’s coverage highlighted a notable increase in product revenue year over year, citing growth from $3.5 million in fiscal 2024 to $9.1 million in fiscal 2025. The research firm attributed that expansion largely to sales of the OneRF Ablation System, which the firm identified as a key driver behind the revenue uptick.
Taken together, the insider sales, recent quarterly results, and the initiation of coverage underscore the continuing volatility and active analyst interest in NeuroOne. The insider transaction was small in dollar terms but comes amid a share price that has declined materially over the prior 12 months and as outside analysts reassess value and growth prospects.
Summary
Mark Christianson sold 917 shares of NeuroOne at $0.8 per share on March 12-13, 2026, for around $733, leaving him with 214,283 shares. NeuroOne’s Q1 fiscal 2026 results showed a $1.4 million net loss on $2.9 million of revenue, slightly beating revenue expectations and recording a smaller loss than forecast. InvestingPro lists the company as potentially undervalued, and Jones Trading started coverage with a Buy rating and a $1.50 target, noting strong product revenue growth tied to the OneRF Ablation System.
Key points
- Insider sale: 917 shares sold by Business Development Director Mark Christianson on March 12 and 13, 2026, at $0.8 per share, totaling about $733.
- Financials: Q1 fiscal 2026 net loss of $1.4 million, or $0.03 per share, with revenue of $2.9 million, modestly above expectations.
- Analyst and platform signals: InvestingPro places NMTC on a Most Undervalued list; Jones Trading initiated coverage with a Buy rating and a $1.50 price target, citing product revenue growth tied to the OneRF Ablation System.
Risks and uncertainties
- Share price weakness: The stock has fallen to $0.72 and is down 30% over the past year, which could affect investor sentiment and liquidity in the near term - impacting public market participants.
- Ongoing losses: The company reported a net loss for Q1 fiscal 2026, indicating continued negative profitability that could pressure capital markets and financing for the medical device sector.
- Concentration of revenue growth: The reported product revenue gains are linked largely to the OneRF Ablation System; reliance on a specific product line can create revenue concentration risk in the medical devices market.